Biblio
Export 1483 results:
Author [ Title
Filters: First Letter Of Last Name is K [Clear All Filters]
“Central Olfactory Dysfunction in Alzheimer's Disease and Mild Cognitive Impairment: A Functional MRI Study.”, J Alzheimers Dis, vol. 59, no. 1, pp. 359-368, 2017.
, “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
, “Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1235-1246, 2018.
, “Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1815-1826, 2018.
, “Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 905-913, 2017.
, “Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study.”, J Alzheimers Dis, vol. 53, no. 2, pp. 497-503, 2016.
, “Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 1, pp. 273-280, 2019.
, “Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 71, no. 1, pp. 273-280, 2019.
, “Cerebral Oxidative Stress and Microvasculature Defects in TNF-α Expressing Transgenic and Porphyromonas gingivalis-Infected ApoE-/- Mice.”, J Alzheimers Dis, vol. 60, no. 2, pp. 359-369, 2017.
, “Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 699-707, 2016.
, “Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 1, pp. 351-7, 2016.
, “Cerebral White Matter Lesions have Low Impact on Cognitive Function in a Large Elderly Memory Clinic Population.”, J Alzheimers Dis, 2018.
, “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
, “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
, “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
, “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
, “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
, “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
, “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
, “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
, “Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.”, J Alzheimers Dis, vol. 57, no. 2, pp. 437-445, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
, “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
,